H. Pylori (Helicobacter Pylori) Test Market Size was valued at USD 2.9 Billion in 2022. The H. Pylori (Helicobacter Pylori) Test market industry is projected to grow from USD 3.06 Billion in 2023 to USD 4.78 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.70% during the forecast period (2023 - 2032).The increased demand for personalized antibiotic therapy and enhanced helicobacter infection diagnosis are the key market drivers expediting the market's expansion.Â
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Market CAGR for H. Pylori (Helicobacter Pylori) Test is being driven by the rising spread of infectious diseases. The prime factors expediting the market’s growth are the increased prevalence of infectious diseases and people's growing knowledge of infections. The most prevalent infectious disorders brought on by bacteria are gonorrhoea, chlamydia, tuberculosis, various STDs, gastroenteritis, and urinary tract infections (UTIs). For instance, the prevalence of peptic ulcers worldwide in 2021 was approximately 8.4%, according to a study with the title "The Prevalence of Peptic Ulcer in the World: a Systematic Review and Meta-analysis" that was published in December 2021. Similar to this, according to a report released by Medscape in April 2021, 4.6 million Americans experience peptic ulcer illness each year. Similar to this, the European Centre for Disease Prevention and Control announced in March 2021 that the European Union, European Economic Area (EEA), and the United Kingdom each identify about 500,000 new cases of sexually transmitted illnesses annually. Instances like these illustrate that the market is anticipated to experience significant expansion over the projected period because helicobacter pylori diagnostics are typically advised for the diagnosis of infectious disorders.
A gram-negative aerobic bacteria commonly found in the stomach is called Helicobacter pylori (H. pylori). While it maintains the ecology of the stomach, it can also infect the inner stomach lining. Infection in the small intestine, gastritis, duodenal ulcers, stomach cancer, and gastric ulcers can all be brought on by the bacterium. This has enhanced the need for H. pylori infection diagnosis tools. In the event that Helicobacter pylori-related ulcers are confirmed, patients must undergo antibiotic therapy for 10 to 14 days.
Short treatment periods and easy access to antibiotics will further increase the demand for pre- and post-monitoring testing as well as the usage of antibiotics. In addition, increasing H. pylori infections, the necessity for early symptom detection, and technical developments in diagnostic methods are some of the reasons propelling the market's expansion. Thus, driving the H. Pylori (Helicobacter Pylori) Test market revenue.
The H. Pylori (Helicobacter Pylori) Test market segmentation, based on test type includes Non-endoscopic, and Endoscopic. With a sizable share of the market, endoscopic category has dominated the market. A process called Helicobacter Pylori Testing with Endoscopy aids in determining whether the stomach contains the Helicobacter pylori (H. pylori) bacteria. An endoscope, a small, flexible tube with inbuilt camera on the end, is inserted via the mouth and into the stomach during this procedure. The camera sends photos to a monitor, enabling the doctor to observe the stomach's inside and determine whether H. pylori is present.
The H. Pylori (Helicobacter Pylori) Test market segmentation, based on technology, includes Immunoassays, Point of care, and Molecular Diagnostics. The immunoassays segment had the biggest market share and is expected to continue to dominate the market over the coming years. For the detection of antibodies, a number of cutting-edge technologies are used, such as enzyme immunoassays. Serology, fast urease tests, and urea breath tests are a few of the indirect tests.
The H. Pylori (Helicobacter Pylori) Test market segmentation, based on end-user, includes Hospitals & clinics, Diagnostic laboratories, and Others. Due to the simplicity of disease presentation, the accessibility of doctors, and the increased occurrence of diseases such duodenal ulcers, stomach cancer, gastritis, and gastric ulcers, as well as infections of the small intestine, hospitals & clinics held the biggest market share.
Figure 1: H. Pylori (Helicobacter Pylori) Test Market, by End-User, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
H. Pylori (Helicobacter Pylori) Test Regional Insights
 By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American H. Pylori (Helicobacter Pylori) Test market area will dominate this market, owing to presence and consistent development of healthcare infrastructure and better economy.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: H. PYLORI (HELICOBACTER PYLORI) TEST MARKET SHARE BY REGION 2022 (USD Billion)
Â
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe H. Pylori (Helicobacter Pylori) Test market accounted for the second-biggest market share due to the increasing count of infectious diseases and rising awareness for diagnostics. Further, the German H. Pylori (Helicobacter Pylori) Test market held the biggest market share, and the UK H. Pylori (Helicobacter Pylori) Test market was the fastest-growing market in the European region
The Asia-Pacific H. Pylori (Helicobacter Pylori) Test Market is expected to grow at the fastest CAGR. This is due to growing cases of H. Pylori disease and growing populations Moreover, China’s H. Pylori (Helicobacter Pylori) Test market held the biggest market share, and the Indian H. Pylori (Helicobacter Pylori) Test market was the fastest growing market in the Asia-Pacific region.
H. Pylori (Helicobacter Pylori) Test Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the H. Pylori (Helicobacter Pylori) Test market, grow even more. Market players are also adopting a variety of strategies to extend their presence, with important market developments including new product innovations, contracts & agreements, mergers &s acquisitions, higher investments, and collaboration with other similar organizations. To expand and survive in a more competitive and rising market climate, the H. Pylori (Helicobacter Pylori) Test industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the H. Pylori (Helicobacter Pylori) Test industry to benefit clients and increase the market sector. In recent years, the H. Pylori (Helicobacter Pylori) Test industry has offered some of the most significant advantages to medicine. Major players in the H. Pylori (Helicobacter Pylori) Test market, including Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), Hoffmann-La Roche Ltd (Switzerland), Quest Diagnostics Incorporated (US), Meridian Bioscience (US), CorisBioconcept SPRL (Belgium), Cardinal Health (US), QIAGEN (Germany), Abbott Laboratories (US), and Biohit Oyj (Finland), and others, are attempting to increase market demand by investing in research and development operations.
The company Biomerica Inc. (Biomerica) creates, produces, and sells medical diagnostic tools for the early identification and follow-up of chronic illnesses and medical problems. Diagnostic test kits from the company are used to examine patient blood, urine, and faecal materials in order to identify various illnesses and medical issues. By utilising enzyme immunoassay technology, it focuses on the development of products for diabetes, gastrointestinal, food intolerances, and esoteric diagnostics. Worldwide, consumers, clinical laboratories, hospitals, and doctor's offices employ the diagnostic tests produced by Biomerica. In May 2022, Helicobacter pylori bacteria are found using the hp+detect diagnostic test from Biomerica, Inc., which just received the CE Mark. After the device has been registered in each country where it will be sold, the corporation will start marketing and selling its hp+detect diagnostic test there and in other nations.
A fully integrated life science company, Meridian Bioscience Inc. (Meridian) creates, produces, and sells diagnostic test kits for the detection of infectious diseases caused by viruses, gastrointestinal disorders, respiratory disorders, and parasites. For use in research and the production of diagnostics, the company also produces bulk antigens, antibodies, purified reagents, nucleotides, and related goods. It creates proteins and other biological components for use in biotechnology studies of novel medications and vaccines. Meridian offers its products to acute care hospitals, outpatient clinics, reference laboratories and physician office laboratories in several countries worldwide. In July 2023, Otsuka America Pharmaceutical, Inc.'s North American BreathTek business will be acquired by Meridian Bioscience, Inc. for $20 million in cash, according to a definitive deal signed by the two parties today. Meridian Bioscience, Inc. is a top producer of testing solutions for diagnosis and life science raw materials globally. The deal is anticipated to be finalize in Meridian's fourth fiscal quarter.
Key Companies in the H. Pylori (Helicobacter Pylori) Test market include
Thermo Fisher Scientific Inc. (US),
Bio-Rad Laboratories, Inc. (US),
Hoffmann-La Roche Ltd (Switzerland),
Quest Diagnostics Incorporated (US),
Meridian Bioscience (US),
CorisBioconcept SPRL (Belgium),
Cardinal Health (US),
QIAGEN (Germany),
Abbott Laboratories (US),
Biohit Oyj (Finland)
H. Pylori (Helicobacter Pylori) Test Industry Developments
April 2021:A Helicobacter pylori Quick Detection Kit called QuickNaviTM-H.pylori was introduced by Otsuka. The diagnostic test uses immunochromatography to determine whether Helicobacter pylori antigens are present or absent in a stool sample. The test kit, which is intended for use in medical facilities, offers a quick assessment in eight minutes by adding three drops of a sample liquid to the kit.
Non-endoscopic
Endoscopic
Immunoassays
Point of care
Molecular Diagnostics
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 2.9 Billion |
| Market Size 2023 | USD 3.06 Billion |
| Market Size 2032 | USD 4.78 Billion |
| Compound Annual Growth Rate (CAGR) | 5.70% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Test Type, Technology, End-User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), Hoffmann-La Roche Ltd (Switzerland), Quest Diagnostics Incorporated (US), Meridian Bioscience (US), CorisBioconcept SPRL (Belgium), Cardinal Health (US) |
| Key Market Opportunities | Developing healthcare infrastructure |
| Key Market Dynamics | Growing prevalence of infectious diseases |
Helicobacter Pylori Test Market Highlights:
Frequently Asked Questions (FAQ) :
The H. Pylori (Helicobacter Pylori) Test market size was valued at USD 2.9 Billion in 2022.
The market is projected to grow at a CAGR of 5.70% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), Hoffmann-La Roche Ltd (Switzerland), Quest Diagnostics Incorporated (US), Meridian Bioscience (US), CorisBioconcept SPRL (Belgium), Cardinal Health (US)
The endoscopic category dominated the market in 2022.
The hospitals & clinics had the largest share in the market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
